93 search results for: symptoms

expert video

UEGW 2024 | Something to Chew On: Exploring Biologics in EoE Management

35 min

Gastroenterology

Prof. Salvatore Oliva and Dr. Milli Gupta discuss the importance of long-term care, multidimensional assessment, and the latest data for biologics.

expert video

Keeping an Eye on Pediatric EoE

2 min

Gastroenterology

Global experts Prof. Arjan Bredenoord and Drs. Ikuo Hirano, Kathryn Peterson, and Evan Dellon discuss identification and assessment of pediatric EoE.

expert video

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

2 min

Rhinology

In this video clip from the EAACI 2024 symposium, Dr. Mullol discusses the challenge of defining active nasal disease using an endoscope.

expert video

Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU

5 min

Dermatology

Dr. Palomares discusses how type 2 inflammation, an aberrant immune response, underlies skin diseases like atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, linking to their clinical symptoms.

expert video

Skin Barrier Dysfunction in AD

4 min

Dermatology

In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel discusses how type 2 inflammation contributes to epidermal barrier dysfunction and AD signs and symptoms.

expert video

Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

15 min

Dermatology

This video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia features Dr. Lisa Weibel presenting how local type 2 inflammation within the skin contributes to epidermal barrier dysfunction, dysbiosis, and neuroimmune dysfunction, leading to the clinical signs and symptoms of AD. Dr. Weibel also reviews how systemic inflammation affects organ systems beyond the skin, and could potentially manifest as atopic and non-atopic comorbidities.

expert video

Diving Below the Surface of AD: The Role of Type 2 Inflammation

10 min

Dermatology

This video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, features Dr. Stephan Weidinger discussing how local type 2 inflammation at the skin tissue level contributes to epidermal barrier dysfunction, dysbiosis, and neuroimmune dysfunction, leading to the clinical signs and symptoms of AD. Dr. Weidinger also reviews how systemic inflammation affects organ systems beyond the skin and can manifest as atopic and non-atopic comorbidities.

expert video

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

5 min

Rhinology

Prof. Hellings and Prof. Corso discuss the significance and rationale behind the new definition of CRSwNP.

expert video

The Burden of Atopic Dermatitis in Children – Daily Pruritis and Sleep Disturbance

2 min

Dermatology

Dr. Mark Koh provides insights on itch and its impact on sleep in children with AD.

expert video

The Path to Nodules: Type 2 Inflammation at the Core of Chronic Itch and Fibrosis in Prurigo Nodularis

11 min

Type 2 Inflammation

Join Dr. Shawn Kwatra in discussing the diverse clinical presentations of PN and the role of type 2 inflammation in disease pathogenesis.

expert video

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?

5 min

Rhinology

Prof. Hellings and Prof. Corso explore the time frame to assess if the patient with CRSwNP has achieved remission

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: BelgiumChange country/region